D-cycloserine (DCS) enhancement of exposure and response prevention (ERP) therapy in panic disorder with agoraphobia: a randomized controlled trial.
- Conditions
- Panic disorder with agorphobia /panic attack with fobia open spaces10002861
- Registration Number
- NL-OMON34949
- Lead Sponsor
- niversiteit Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Withdrawn
- Sex
- Not specified
- Target Recruitment
- 72
Adults patients (between 18 and 55 years) with panic disorder + agoraphobia (PD+AGO), according to DSM-IV diagnoses as established using standardized interviews. And are referred to the outpatient clinic of one of the participating centres.
Patients with :
- co-morbided psychiatric disorders (severe major depressive disorder, bipolar disorder, psychosis, dependence and abuse of alcohol, drugs in the past three months)
- mental deficiency
- inability to adequately read or speak Dutch
- (a history of) neurological disease (i.e. neurovascular disease, movement disorders, seizures, dementia), renal or liver abnormalities, and a history of allergies, adverse reactions or rash on medication.
- Currently taking benzodiazepines, since benzodiazepine might hamper therapy effect.
- Pregnancy or breastfeeding at the time of the study
- use of isoniazide and cycloserines.
- use of variable dosages of antidepressiva (SSRI*s of TCA)( the use of a fixed dosage of antidepressiva is NOT an exclusion criterium)
- An evidence based behavioural therapy for panic disorder during the past 12 month.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary outcome measures will be:<br /><br>- the Panic Disorder Severity Scale (PDSS; Shear et al. 1997; taken weekly<br /><br>before each session)<br /><br>- the Subjective Unit of Distress Scale (SUDS; Wolpe 1969), taken weekly before<br /><br>and after each session.</p><br>
- Secondary Outcome Measures
Name Time Method